arrow
M

Mark C. Petrie

british heart foundation
H指数:95
被引数:4.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Revascularization of coronary artery disease in heart failure: a European Journal of Heart Failure expert consensus statement

心力衰竭患者冠状动脉疾病再血管化治疗:欧洲心力衰竭杂志专家共识声明

2026-07-240
OAAI
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials

心衰伴射血分数保留或轻度降低患者中的Ziltivekimab:ATHENA和HERMES试验的背景与设计

2026-01-010
OA
Performance of prediction models for incident heart failure and heart failure hospitalization in individuals with type 2 diabetes: a systematic review and meta-analysis

2型糖尿病患者中新发心力衰竭和心力衰竭住院预测模型的性能:一项系统评价和荟萃分析

2026-01-010
OA
Management of Ischemic Heart Disease in Patients With Heart Failure

缺血性心脏病合并心力衰竭患者的管理

2025-12-010
PRE
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

司美格鲁肽在肥胖相关的心衰伴射血分数保留中不同年龄范围的效果:STEP-HFpEF项目的发现

2025-11-250
OAAI
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure

II期、随机、双盲、安慰剂对照研究,评估CRD-740(一种PDE9抑制剂)在慢性心力衰竭中的应用

2025-10-310
PRE
European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

《欧洲心力衰竭杂志》共识声明。射血分数降低的心力衰竭合并房颤患者的药物治疗:证据回顾与行动倡议

2025-10-220
OAAI
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma

黑色素瘤患者中BRAF和MEK抑制剂心血管效应的前瞻性评估

2025-10-100
OAAI
Semaglutide and Exercise Function in Obesity-Related HFpEF

司美格鲁肽和运动功能在肥胖相关HFpEF中的作用

2025-10-030
PRE
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

SGLT2抑制剂在心力衰竭的预防和治疗中的应用:HFA和HFAI的科学声明

2025-09-190
OAAI
Frailty and Effects of Semaglutide in Obesity-Related HFpEF

虚弱及司美格鲁肽在肥胖相关HFpEF中的效果

2025-09-150
OAAI
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

心力衰竭伴或不伴糖尿病和慢性肾脏病的患者接受心肌梗死后 empa gliflozin 治疗的疗效:来自 EMPACT-MI 的启示

2025-09-140
OAAI